Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications
New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, have been recently approved for primary and secondary prophylaxis of thromboembolic conditions. However, there is no clear strategy for managing and reversing their anticoagulant effects. We aimed to summarize the available ev...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707037/ |